AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30376893
Drug: TXA dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA dose A
Trial: 30376893
Drug: TXA dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA dose B
Trial: 20520555
Drug: Colloid infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid infusions (HES and human albumin)
Trial: 20520555
Drug: Colloids vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloids vs. lactated Ringer's solution
Trial: 17431368
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation utilizing intensity modulated external beam radiation therapy or brachytherapy
Trial: 7740638
Drug: Stroke unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke unit treatment using Bobath principles
Trial: 7740638
Drug: General medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General medical unit treatment
Trial: 2161614
Drug: Diet A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet A: 227 g canned beans daily in a single dose
Trial: 2161614
Drug: Diet B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet B: 227 g canned beans daily in a divided dose
Trial: 2161614
Drug: Diet C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet C: 182 g canned beans daily in a divided dose
Trial: 7217721
Drug: Killed influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed influenza virus vaccine (A/New Jersey/76)
Trial: 27979988
Drug: Histamine receptor
RxNorm normalized name: Histamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine receptor antagonist
Trial: 27979988
Drug: Histamine receptor
RxNorm normalized name: Histamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine receptor blockade
Trial: 24162809
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + PCV chemotherapy
Trial: 21134328
Drug: HPHchol diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPHchol diet (high-protein high-cholesterol); 590 mg cholesterol; 2 eggs per day; duration 12 weeks
Trial: 21134328
Drug: HPLchol diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPLchol diet (high-protein low-cholesterol); 213 mg cholesterol; replaced eggs with 100 g of lean animal protein; duration 12 weeks
Trial: 19303978
Drug: Control (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.04 g/min glucose)
Trial: 19303978
Drug: High (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High (0.8 g/min glucose)
Trial: 19402905
Drug: Loozit group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loozit group weight management program (G)
Trial: 19402905
Drug: Loozit group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loozit group weight management program plus additional therapeutic contact (G+ATC)
Trial: 16137403
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity)
Trial: 12045491
Drug: TDF 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 75 mg
Trial: 12045491
Drug: TDF 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 150 mg
Trial: 7237926
Drug: [14C]‐glycocholic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [14C]‐glycocholic acid (bolus injection or constant infusion)
Trial: 24866329
Drug: mitiglinide/voglibose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mitiglinide/voglibose combination
Trial: 22306193
Drug: AZD1236 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1236 75 mg twice daily for 6 weeks
Trial: 16550603
Drug: Cisplatin administered
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered intravenously (IV, 100 mg/m2)
Trial: 16550603
Drug: Cisplatin administered
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered intra-arterially (IA, 150 mg/m2)
Trial: 12491212
Drug: Minocycline-ethylenediaminetetraacetate (M-EDTA)
RxNorm normalized name: ethylenediaminetetraacetate
DrugBank: Edetic acid (DB00974)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline-ethylenediaminetetraacetate (M-EDTA) lock solution
Trial: 12491212
Drug: Heparin flush
RxNorm normalized name: heparin flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin flush (Control)
Trial: 1756285
Drug: Otilonium bromide
RxNorm normalized name: otilonium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilonium bromide (OB) 40 mg tid
Trial: 7017982
Drug: Cimetidine, 300
RxNorm normalized name: Cimetidine, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 300 mg IV every 6 hours
Trial: 7017982
Drug: Antacid titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid titration to maintain gastric pH > 4.0
Trial: 19641042
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by concurrent chemoradiation in SCCHN patients (TAX 324 trial)
Trial: 9783350
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day sertraline
Trial: 9783350
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day imipramine
Trial: 3279969
Drug: Complamin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complamin (1 g t.i.d.)
Trial: 3279969
Drug: Cholestyramine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (4 g b.i.d.)
Trial: 3279969
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Complamin and cholestyramine
Trial: 23587943
Drug: Artesunate plus
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate plus sulfadoxine-pyrimethamine (AS+SP) with primaquine (0.75 mg/kg) on day 2
Trial: 21512491
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of IRS 19
Trial: 21512491
Drug: Irrigation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigation of the nasopharynx with saline solutions
Trial: 17002812
Drug: Unilateral lower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral lower limb suspension (ULLS) for 20 days
Trial: 11672942
Drug: Oral flupenthixol
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral flupenthixol (2.5 or 5.0 mg; p.o.)
Trial: 11672942
Drug: Intramuscular flupenthixol
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular flupenthixol decanoate (10 or 20 mg; i.m.)
Trial: 11672942
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose flupenthixol
Trial: 3034040
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 to 10 mg daily) - once-daily administration
Trial: 3034040
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 to 10 mg daily) - twice-daily administration
Trial: 3034040
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 to 10 mg daily)
Trial: 29354931
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (EA + Mulligan's mobilization)
Trial: 27319970
Drug: ABT‐126 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐126 50 mg
Trial: 23660378
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (AA + lipid group)
Trial: 23660378
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (high AA + lipid group)
Trial: 23660378
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g AA kg(‐1) · d(‐1) (control group)
Trial: 21908683
Drug: Platelet glycoprotein
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet glycoprotein IIb/IIIa inhibitor
Trial: 21908683
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with abciximab and Angioguard(®) embolic protection
Trial: 7999812
Drug: Intraperitoneal antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal antibiotics (Cephalothin, cefazolin, vancomycin, ceftazidime, aminoglycosides tobramycin and gentamicin)
Trial: 7999812
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug therapy
Trial: 7999812
Drug: Initial intraperitoneal
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial intraperitoneal therapy for both gram-positive and gram-negative bacteria
Trial: 3057482
Drug: Dextropropoxyphene (DXP)
RxNorm normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene (DXP) 130 mg
Trial: 3057482
Drug: Dextropropoxyphene (DXP)
RxNorm normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene (DXP) 65 mg + Amitriptyline (AMI) 25 mg
Trial: 3057482
Drug: Indomethacin (IN)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (IN) 50 mg
Trial: 31757517
Drug: Lifetime history
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifetime history of injecting drug use
Trial: 24285938
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg/day for 8 weeks
Trial: 24285938
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg/day for 8 weeks
Trial: 16864110
Drug: Deoxyribonucleotidum injection
RxNorm normalized name: Adenine Deoxyribonucleoside
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deoxyribonucleotidum injection
Trial: 12704355
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 30 mg (n = 464)
Trial: 10634340
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with supplemental oxygen
Trial: 1348061
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg, four times daily for 3 weeks
Trial: 27457255
Drug: High-dose implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose implant
Trial: 27457255
Drug: Low-dose implant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose implant
Trial: 20179212
Drug: Siltuximab 6
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Siltuximab 6 mg/kg every 2 weeks
Trial: 20179212
Drug: Siltuximab 9
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Siltuximab 9 mg/kg every 3 weeks
Trial: 16224086
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group from phase III ischemic stroke therapy trials
Trial: 12392866
Drug: Timing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing of administration close to study closeout
Trial: 9920089
Drug: low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose recombinant human LH (r-hLH) (150 IU, twice daily)
Trial: 9920089
Drug: high dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose recombinant human LH (r-hLH) (375 IU, twice daily)
Trial: 7661074
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral anticoagulant and antiplatelet therapy
Trial: 2292620
Drug: Culturally sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally sensitive modeling therapy
Trial: 7024156
Drug: mianserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin (10 mg nocte)
Trial: 24188573
Drug: Multi-level intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-level intervention to reduce antibiotic prescribing
Trial: 15497908
Drug: Drospirenone (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone (1, 2 or 3 mg) combined with estradiol (1 mg)
Trial: 7959187
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated tablets
Trial: 3496848
Drug: Cefoxitin, piperacillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin, piperacillin, cefoperazone, and aztreonam administered intravenously for 9 days
Trial: 23802352
Drug: Intervention A
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention A (weekly training courses with therapy sessions)
Trial: 20812020
Drug: 2 l
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 l PEG combined with 36 mg senna glycosides in tablets
Trial: 20812020
Drug: 4 l
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l PEG
Trial: 19929645
Drug: On-site provision
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site provision of implants and IUDs at Site B
Trial: 15255284
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ospemifene
Trial: 15255284
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ospemifene
Trial: 15255284
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg ospemifene
Trial: 11750186
Drug: Nimodipine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (90 mg)
Trial: 9259934
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin for 7 days in addition to routine prophylactic intravenous ampicillin
Trial: 3687352
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: microaggregate‐poor erythrocyte concentrate (SAGM‐ERC) plus 3% dextran‐60 as plasma substitute, postoperative analgesia with intramuscular ketobemidone
Trial: 17445811
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (CC and rFSH)
Trial: 15456082
Drug: Hormone levels
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone levels
Trial: 10207592
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g x 2/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Trial: 10207592
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g x 3/day) + Amikacin (7.5 mg.kg‐1 x 2/day)
Trial: 8549245
Drug: 8 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 Gy radiation therapy (single fraction)
Trial: 8549245
Drug: 12 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 Gy radiation therapy
Trial: 8549245
Drug: 18 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 Gy radiation therapy
Trial: 8549245
Drug: 24 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 Gy radiation therapy
Trial: 2755259
Drug: Clebopride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clebopride (0.5 mg/kg)
Trial: 2755259
Drug: Clebopride (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clebopride (0.75 mg/kg)
Trial: 2755259
Drug: Clebopride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clebopride (1 mg/kg)
Trial: 2755259
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg/kg)
Trial: 31638010
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single dose 20 mg/kg, administered twice a year for 2 years)
Trial: 31638010
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of azithromycin (6 months apart)
Trial: 31638010
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of azithromycin
Trial: 31638010
Drug: 4 doses
RxNorm normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 doses of azithromycin
Trial: 27936524
Drug: Generic clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic clopidogrel product (75 mg once daily for 7 days)
Trial: 27936524
Drug: Reference clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference clopidogrel product (75 mg once daily for 7 days)
Trial: 26348588
Drug: Treatment-as-usual (medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (medication alone)
Trial: 23494740
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of GaCr milk powder
Trial: 22566310
Drug: Glutamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.5 g/kg/day for 5 days as continuous perfusion)
Trial: 18162017
Drug: 2-g E-EPA
RxNorm normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2-g E-EPA
Trial: 15077311
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) at weeks 0, 2, and 6
Trial: 11513820
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (10,000 lux for 30 min, from 6:00 AM to 6:30 AM)
Trial: 7828189
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of riboflavin as a single oral dose for at least 3 months
Trial: 7828189
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of riboflavin plus 75 mg of aspirin
Trial: 2556883
Drug: RIT 4237
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT 4237 oral rotavirus vaccine
Trial: 28475671
Drug: Dabrafenib plus
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib plus trametinib (dabrafenib 150 mg twice daily + trametinib 2 mg once daily)
Trial: 21355147
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Piracetam tablet)
Trial: 19041440
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD) OCP (30 mcg EE/150 mcg DSG)
Trial: 19041440
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose (VLD) OCP (20 mcg EE/150 mcg DSG)
Trial: 19041440
Drug: EE-only phase
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EE-only phase (10 mcg EE) in group VLD
Trial: 17953131
Drug: Drama therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drama therapy program
Trial: 15372846
Drug: statin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: statin monotherapy (10, 20, 40 mg/day or 80 mg/day)
Trial: 11552903
Drug: Budesonide controlled
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide controlled ileal release 6 mg o.m.
Trial: 11552903
Drug: Budesonide controlled
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide controlled ileal release flexible dosing (3, 6 or 9 mg o.m.)
Trial: 7522721
Drug: Conventional salvage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional salvage therapy
Trial: 7522721
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy with subsequent autologous bone marrow transplantation (HDC/ABMT)
Trial: 7522721
Drug: Long-term continuous
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term continuous complete remission (cCR) with salvage therapy
Trial: 23468128
Drug: Cabergoline (0.5‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.5‐1 mg/week up to 3.0 mg/week) followed by ketoconazole (200 mg/day to 600 mg/day)